584 related articles for article (PubMed ID: 31764959)
1. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
[TBL] [Abstract][Full Text] [Related]
2. Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Zimmer JA; Shcherbinin S; Devous MD; Bragg SM; Selzler KJ; Wessels AM; Shering C; Mullen J; Landry J; Andersen SW; Downing AM; Fleisher AS; Svaldi DO; Sims JR
Alzheimers Dement (N Y); 2021; 7(1):e12123. PubMed ID: 33614894
[TBL] [Abstract][Full Text] [Related]
3. Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).
Sims JR; Selzler KJ; Downing AM; Willis BA; Aluise CD; Zimmer J; Bragg S; Andersen S; Ayan-Oshodi M; Liffick E; Eads J; Wessels AM; Monk S; Schumi J; Mullen J
J Prev Alzheimers Dis; 2017; 4(4):247-254. PubMed ID: 29181490
[TBL] [Abstract][Full Text] [Related]
4. BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.
Sakamoto K; Matsuki S; Matsuguma K; Yoshihara T; Uchida N; Azuma F; Russell M; Hughes G; Haeberlein SB; Alexander RC; Eketjäll S; Kugler AR
J Clin Pharmacol; 2017 Nov; 57(11):1460-1471. PubMed ID: 28618005
[TBL] [Abstract][Full Text] [Related]
5. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
6. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
8. Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial.
Koch G; Motta C; Bonnì S; Pellicciari MC; Picazio S; Casula EP; Maiella M; Di Lorenzo F; Ponzo V; Ferrari C; Scaricamazza E; Caltagirone C; Martorana A
JAMA Netw Open; 2020 Jul; 3(7):e2010372. PubMed ID: 32667654
[TBL] [Abstract][Full Text] [Related]
9. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
10. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Green RC; Schneider LS; Amato DA; Beelen AP; Wilcock G; Swabb EA; Zavitz KH;
JAMA; 2009 Dec; 302(23):2557-64. PubMed ID: 20009055
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
12. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Fullerton T; Binneman B; David W; Delnomdedieu M; Kupiec J; Lockwood P; Mancuso J; Miceli J; Bell J
Alzheimers Res Ther; 2018 Apr; 10(1):38. PubMed ID: 29622037
[TBL] [Abstract][Full Text] [Related]
14. AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.
Cebers G; Alexander RC; Haeberlein SB; Han D; Goldwater R; Ereshefsky L; Olsson T; Ye N; Rosen L; Russell M; Maltby J; Eketjäll S; Kugler AR
J Alzheimers Dis; 2017; 55(3):1039-1053. PubMed ID: 27767991
[TBL] [Abstract][Full Text] [Related]
15. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
17. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.
Sperling R; Henley D; Aisen PS; Raman R; Donohue MC; Ernstrom K; Rafii MS; Streffer J; Shi Y; Karcher K; Raghavan N; Tymofyeyev Y; Bogert J; Brashear HR; Novak G; Thipphawong J; Saad ZS; Kolb H; Rofael H; Sanga P; Romano G
JAMA Neurol; 2021 Mar; 78(3):293-301. PubMed ID: 33464300
[TBL] [Abstract][Full Text] [Related]
18. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
[TBL] [Abstract][Full Text] [Related]
19. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
20. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Dysken MW; Sano M; Asthana S; Vertrees JE; Pallaki M; Llorente M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Zachariah S; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Segal Y; Peduzzi PN; Guarino PD
JAMA; 2014 Jan; 311(1):33-44. PubMed ID: 24381967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
